ArticleBritish journal of pharmacology2007
Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506.
Article in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.Allergy · 2026Guideline
- Immunological Basis of Chronic Spontaneous Urticaria: Immunoglobulin E and Beyond.Yonsei medical journal · 2026Review
- Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond.The journal of allergy and clinical immunology. In practice · 2026Review
- Clinical applications of tacrolimus in the treatment of ocular diseases: a narrative literature review.International ophthalmology · 2025Review
- Mast Cells in Allergic and Non-Allergic Upper Airways Diseases: Sentinel in the Watchtower.International journal of molecular sciences · 2024Review
- Mast cell stabilizers: from pathogenic roles to targeting therapies.Frontiers in immunology · 2024Review
- Chronic urticaria treatment challenges in children.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2024Review
- Mast Cells in Upper and Lower Airway Diseases: Sentinels in the Front Line.International journal of molecular sciences · 2023Review
- Review
- Urticaria.Nature reviews. Disease primers · 2022Review
- Efficacy and Safety of Tacrolimus in the Treatment of Pediatric Henoch-Schönlein Purpura Nephritis.Paediatric drugs · 2022Article
- Immunological signature of chronic spontaneous urticaria (Review).Experimental and therapeutic medicine · 2022Review
- Immunometabolism in biofilm infection: lessons from cancer.Molecular medicine (Cambridge, Mass.) · 2022Review
- Calcineurin Aα Contributes to IgE-Dependent Mast-Cell Mediator Secretion in Allergic Inflammation.Journal of innate immunity · 2022Article
- ATP/IL-33-triggered hyperactivation of mast cells results in an amplified production of pro-inflammatory cytokines and eicosanoids.Immunology · 2021Article
- Drug Repurposing to Treat Glucocorticoid Resistance in Asthma.Journal of personalized medicine · 2021Article
- Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.Journal of asthma and allergy · 2021Review
- Should mast cells be considered therapeutic targets in multiple sclerosis?Neural regeneration research · 2020Review
- Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria: A Systematic Review.Allergy, asthma & immunology research · 2019Article
- Targeting of Basophil and Mast Cell Pro-Allergic Reactivity Using Functionalised Gold Nanoparticles.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeCyclosporine and FK506 are thought to act by targeting the Ca2+-dependent protein phosphatase, calcineurin. The aim of the present study was to determine whether cyclosporine and FK506 stabilize mast cells and basophils by interacting with calcineurin. EXPERIMENTAL APPROACH: The effects of cyclosporine and FK506 on the IgE-mediated release of histamine from mast cells and basophils were evaluated. The presence of calcineurin in cells was determined by Western blotting. Ca2+-dependent protein phosphatase activities were assessed in cell extracts using a synthetic phosphorylated peptide that is known to serve as a substrate for calcineurin. KEY
resultsFK506 was about 100-fold more potent than cyclosporine as an inhibitor of IgE-dependent histamine release from mast cells and basophils. Immunoblotting of solubilized preparations of purified cells demonstrated the presence of calcineurin in mast cells and basophils. In enzyme assays, mast cells expressed approximately 7-fold higher Ca2+-dependent protein phosphatase activity than basophils. Whereas cyclosporine effectively inhibited Ca2+-dependent protein phosphatase activity in cell extracts, FK506 was considerably less effective. CONCLUSIONS AND IMPLICATIONS: FK506 and cyclosporine inhibit the stimulated release of histamine from mast cells and basophils. However, the ability of cyclosporine, but not FK506, to inhibit Ca2+-dependent protein phosphatase activity questions whether FK506 stabilizes mast cells and basophils by interacting with calcineurin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.